To assess for direct effects of AR in mediating this transcriptional reprogramming we leveraged the preclinical model of MYC-driven prostate cancer and performed binding and expression target analysis (BETA) to integrate MYC-driven gene expression changes in murine VP with genome-wide AR binding data40. This evidence concerns the gene AR and prostate cancer.